Previous product
Back to products
Tibsovo (ivosidenib)
CHF38,438.32
Next product
Rozlytrek (entrectinib)
CHF7,983.63
Piqray (alpelisib)
CHF7,700.00
Piqray (alpelisib) is a medication used in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CAmutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
Category: Oncology
Reviews
There are no reviews yet.